Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

Key Takeaways IMVT posted an adjusted Q1 loss of $0.60 per share, beating estimates and matching the year-ago quarter loss.Lead drug IMVT-1402 is being studied for 6 indications, with key data readouts on track through 2027.IMVT's cash balance of $598.9M is expected to fund clinical activities, including IMVT-1402.Immunovant, Inc. (IMVT) reported first-quarter fiscal 2026 adjusted net loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, the c ...